PURPOSE: The objective of this study was to evaluate the performance of acellular human dermis reinforcement during laparoscopic hiatal hernia repair. METHODS: A prospective non-randomized, single institution study enrolled patients undergoing laparoscopic hiatal hernia repair. Acellular human dermis, FlexHD (Musculoskeletal Transplant Foundation, Edison, NJ) or AlloDerm (LifeCell Inc., Branchburg, NJ) were used to buttress the repair after primary closure. A protocol barium swallow (BAS) was performed at 6 months and then as needed due to clinical indications. Primary outcome measure was recurrence. Patients completed preoperative and postoperative GERD symptom questionnaires and quality of life surveys (SF-36). Kruskal-Wallis ANOVA, Student's t test, Fisher's exact test, or Wilcoxon signed-rank test were utilized as appropriate (p < 0.05 considered statistically significant). RESULTS: Fifty-four patients (10 men and 44 women) with a mean age of 62 ± 10 years underwent laparoscopic hiatal hernia repair using Flex HD (n = 37) or AlloDerm (n = 17). Both groups were similar with respect to gender, age, hiatus size, hernia type [sliding/Type I (n = 14) or paraesophageal/Type III/IV (n = 40)], esophageal motor function (manometry), preoperative SF-36 quality of life surveys, and GERD symptom questionnaires. Forty-seven patients (87 %) completed the BAS at 6 months; each group had two recurrences (p = 0.597). At median follow-up of 33 months, there were 3 recurrences (18 %) in the AlloDerm group and 5 recurrences (14 %) in the Flex HD group (p = 0.365). Minimal differences in GERD symptoms or SF-36 scores were detected between groups. However, anti-reflux medication usage, GERD symptoms, and quality of life significantly improved for both groups after laparoscopic hiatal hernia repair. CONCLUSIONS: Laparoscopic hiatal hernia repair with acellular human dermis reinforcement results in improvement of GERD-related symptoms and quality of life without mesh-associated complications. The type of acellular human dermis did not influence recurrence rate.
PURPOSE: The objective of this study was to evaluate the performance of acellular human dermis reinforcement during laparoscopic hiatal hernia repair. METHODS: A prospective non-randomized, single institution study enrolled patients undergoing laparoscopic hiatal hernia repair. Acellular human dermis, FlexHD (Musculoskeletal Transplant Foundation, Edison, NJ) or AlloDerm (LifeCell Inc., Branchburg, NJ) were used to buttress the repair after primary closure. A protocol barium swallow (BAS) was performed at 6 months and then as needed due to clinical indications. Primary outcome measure was recurrence. Patients completed preoperative and postoperative GERD symptom questionnaires and quality of life surveys (SF-36). Kruskal-Wallis ANOVA, Student's t test, Fisher's exact test, or Wilcoxon signed-rank test were utilized as appropriate (p < 0.05 considered statistically significant). RESULTS: Fifty-four patients (10 men and 44 women) with a mean age of 62 ± 10 years underwent laparoscopic hiatal hernia repair using Flex HD (n = 37) or AlloDerm (n = 17). Both groups were similar with respect to gender, age, hiatus size, hernia type [sliding/Type I (n = 14) or paraesophageal/Type III/IV (n = 40)], esophageal motor function (manometry), preoperative SF-36 quality of life surveys, and GERD symptom questionnaires. Forty-seven patients (87 %) completed the BAS at 6 months; each group had two recurrences (p = 0.597). At median follow-up of 33 months, there were 3 recurrences (18 %) in the AlloDerm group and 5 recurrences (14 %) in the Flex HD group (p = 0.365). Minimal differences in GERD symptoms or SF-36 scores were detected between groups. However, anti-reflux medication usage, GERD symptoms, and quality of life significantly improved for both groups after laparoscopic hiatal hernia repair. CONCLUSIONS: Laparoscopic hiatal hernia repair with acellular human dermis reinforcement results in improvement of GERD-related symptoms and quality of life without mesh-associated complications. The type of acellular human dermis did not influence recurrence rate.
Authors: Corey R Deeken; Braden J Eliason; Matthew D Pichert; Sheila A Grant; Margaret M Frisella; Brent D Matthews Journal: Ann Surg Date: 2012-03 Impact factor: 12.969
Authors: M Hashemi; J H Peters; T R DeMeester; J E Huprich; M Quek; J A Hagen; P F Crookes; J Theisen; S R DeMeester; L F Sillin; C G Bremner Journal: J Am Coll Surg Date: 2000-05 Impact factor: 6.113
Authors: Brant K Oelschlager; Carlos A Pellegrini; John Hunter; Nathaniel Soper; Michael Brunt; Brett Sheppard; Blair Jobe; Nayak Polissar; Lee Mitsumori; James Nelson; L Swanstrom Journal: Ann Surg Date: 2006-10 Impact factor: 12.969
Authors: Eelco B Wassenaar; Fernando Mier; Huseyin Sinan; Rebecca P Petersen; A Valeria Martin; Carlos A Pellegrini; Brant K Oelschlager Journal: Surg Endosc Date: 2011-11-16 Impact factor: 4.584
Authors: Rudolf J Stadlhuber; Amr El Sherif; Sumeet K Mittal; Robert J Fitzgibbons; L Michael Brunt; John G Hunter; Tom R Demeester; Lee L Swanstrom; C Daniel Smith; Charles J Filipi Journal: Surg Endosc Date: 2008-12-06 Impact factor: 4.584
Authors: Stavros A Antoniou; Beat P Müller-Stich; George A Antoniou; Gernot Köhler; Ruzica-Rosalia Luketina; Oliver O Koch; Rudolph Pointner; Frank-Alexander Granderath Journal: Langenbecks Arch Surg Date: 2015-06-07 Impact factor: 3.445
Authors: Benjamin Clapp; Ali M Kara; Paul J Nguyen-Lee; Hani M Annabi; Luis Alvarado; John D Marr; Omar M Ghanem; Brian Davis Journal: Surg Endosc Date: 2022-08-11 Impact factor: 3.453
Authors: Michael T Olson; Saurabh Singhal; Roshan Panchanathan; Sreeja Biswas Roy; Paul Kang; Taylor Ipsen; Sumeet K Mittal; Jasmine L Huang; Michael A Smith; Ross M Bremner Journal: Surg Endosc Date: 2018-05-14 Impact factor: 4.584